MLTX Stock Summary and Trading Ideas (Moonlake Immunotherapeutics - Class A | NASDAQ:MLTX)

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Moonlake Immunotherapeutics - Class A trades on the NASDAQ stock market under the symbol MLTX.

As of December 26, 2025, MLTX stock price declined to $13.83 with 855,237 million shares trading.

MLTX has a beta of -0.24, meaning it tends to be less sensitive to market movements. MLTX has a correlation of 0.00 to the broad based SPY ETF.

MLTX has a market cap of $979.82 million. This is considered a Small Cap stock.

In the last 3 years, MLTX traded as high as $64.98 and as low as $5.95.

The top ETF exchange traded funds that MLTX belongs to (by Net Assets): VHT, ESML, MSSM, SBIO, NUSC.

MLTX has underperformed the market in the last year with a price return of -73.7% while the SPY ETF gained +16.0%. MLTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.4% and -5.3%, respectively, while the SPY returned +4.7% and +0.7%, respectively.

MLTX support price is $13.26 and resistance is $14.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLTX shares will trade within this expected range on the day.